|
Printable version |
From: | "G Stolwyk" <stolwyk@wave.co.nz> |
Date: | Sat, 14 Dec 2002 13:36:09 +1300 |
This Phase II trial concerns Ovarian cancer and has
started.
From the recent announcement by MEI:
"A total of approximately 40 women who have already failed other forms of chemotherapy will be enrolled in the trial in the first instance. Patients will receive phenoxodiol by intravenous injection on two consecutive days per week for a treatment cycle lasting 12 weeks". My comment: 1. A very good sample. One can see that some time has been spent on the selection. 2. dr Mor's favourite Trial Phase II. This is the one to watch alright because of Phenoxodiol's success in killing this Ovarian cancer in the laboratory. 3. The high powered Yale Uni medical team includes dr Rutherford. He and dr Mor will be in charge of the Trial. It is clear that nothing is left to chance. 4. The Trial will last for 12 weeks only. That will be good news for the investor as he may perhaps get some news at the earliest time. 5. Use of Phenoxodiol only. A high powered team, a good sample and hopefully an early success. |
|